HemangioendotheliomaSymptoms, Doctors, Treatments, Advances & More
Hemangioendothelioma Overview
Learn About Hemangioendothelioma
- Hemangioendothelioma
Silvia Stacchiotti practices practicing medicine in Milan, Italy. Ms. Stacchiotti is rated as an Elite expert by MediFind in the treatment of Hemangioendothelioma. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Solitary Fibrous Tumor, Adult Soft Tissue Sarcoma, Hemangioendothelioma, Epithelioid Sarcoma, and Synovectomy.
Indian River Health Services Inc
Jonathan Braue is a Dermatologist practicing medicine in Vero Beach, Florida. Dr. Braue is rated as an Advanced provider by MediFind in the treatment of Hemangioendothelioma. He is also highly rated in 56 other conditions, according to our data. His clinical expertise encompasses Sunburn, Actinic Keratosis, Warts, and Seborrheic Keratosis. Dr. Braue is board certified in American Board Of Dermatology, 2019. Dr. Braue is currently accepting new patients.
Avera Medical Group Dermatology — Mitchell
Mandi Greenway is a Dermatologist practicing medicine in Mitchell, South Dakota. Dr. Greenway is rated as an Advanced provider by MediFind in the treatment of Hemangioendothelioma. She is also highly rated in 34 other conditions, according to our data. Her clinical expertise encompasses Actinic Keratosis, Warts, Seborrheic Keratosis, and Melanoma. Dr. Greenway is board certified in American Board Of Dermatology. Dr. Greenway is currently accepting new patients.
Summary: The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin, pazopanib, surgery, and maintenance pazopanib, with or without RT. * To characterize the pharmacokinetics of pazopanib and doxorubicin in combination with ifosfamide in inte...
Summary: This randomized clinical trial evaluates if low-dose sirolimus (target trough 4-8 ng/mL) combined with prednisolone is noninferior in efficacy but superior in safety compared to standard high-dose sirolimus (target trough 10-15 ng/mL) combined with prednisolone in pediatric patients with kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon (KHE with KMP), with participants randomized 1:...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center


